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Abstract: The phenotype of HTLV-1-transformed CD4
+ T lymphocytes largely depends 
on defined viral effector molecules such as the viral oncoprotein Tax. In this review, we 
exemplify the expression pattern of characteristic lineage markers, costimulatory receptors 
and  ligands  of  the  tumor  necrosis  factor  superfamily,  cytokine  receptors,  and  adhesion 
molecules on HTLV-1-transformed cells. These molecules may provide survival signals for 
the  transformed  cells.  Expression  of  characteristic  surface  markers  might  therefore 
contribute to persistence of HTLV-1-transformed lymphocytes and to the development of 
HTLV-1-associated disease. 
Keywords:  HTLV-1;  Tax;  oncoprotein;  phenotype;  differentiation;  ATLL;  HAM/TSP; 
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1. Pathogenetic Properties of Human T Cell Lymphotropic Virus Type 1 (HTLV-1) 
Human T cell lymphotropic virus type 1 (HTLV-1), a delta-retrovirus, is the causative agent of a 
severe  and  fatal  lymphoproliferative  disorder  of  CD4
+  T  cells,  adult  T  cell  leukemia/lymphoma 
(ATLL), and of a neurodegenerative, inflammatory disease, HTLV-1-associated myelopathy/ tropical 
spastic paraparesis (HAM/TSP) [1–5]. Both diseases can develop as a consequence of prolonged viral 
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persistence in T cells after a latency of decades. The risk of developing ATLL among virus carriers is 
estimated to be 6.6% for males and 2.1% for females, while 1–4% of the infected individuals may 
develop HAM/TSP [6,7]. HTLV-1 has developed a unique strategy  for lifelong persistence in  the 
presence  of  an  active  immune  system.  This  is  achieved  by  replication  of  the  virus  mainly  in  its 
provirus form, stimulation of cell division by the virus, and, as a consequence, clonal amplification of 
infected  cells.  Virus-infected  clones  are  detectable  and  can  persist  over  many  years  even  in 
non-leukemic  individuals  [8].  The  stimulation  of  T  cell  proliferation  in  patients  by  viral  gene 
expression  was  corroborated  by  cell  dynamic  studies  which  revealed  a  correlation  of  the  in vivo 
proliferation rate of CD4
+CD45R0
+ cells, the main cell type infected with HTLV-1 in vivo [9], with 
viral expression ex vivo [10]. 
2. Viral Effector Molecules 
Upon  infection,  HTLV-1  integrates  into  the  host  cell  genome  and  is  mainly  maintained  in  its 
provirus form (9.1 kb) which is flanked by long terminal repeats (LTR) in both the 5′ and 3′ region. In 
addition to structural proteins common for retroviruses, protease, and reverse transcriptase, HTLV-1 
encodes accessory and regulatory proteins [6]. While the accessory proteins p12, p30, p13 and HBZ 
are important for viral infectivity and replication, they are not required for lymphocyte immortalization 
[11,12]. HBZ, which is transcribed as an antisense transcript of HTLV-1 from the 3′ LTR, promotes 
proliferation of ATLL cells [13]. The regulatory proteins Tax and Rex are both essential for viral 
replication  [14].  While  Tax  strongly  enhances  viral  mRNA  synthesis  by  transactivating  the  
HTLV-1-LTR promoter, Rex controls the synthesis of the structural proteins on a posttranscriptional 
level [15,16]. 
Tax  confers  transforming  properties  on  HTLV-1,  as  it  can  immortalize  primary  human  T  cells  
[17–19], and induce leukemia in transgenic mice [20]. Several Tax functions may contribute to its 
transforming capacity, including interference with cell cycle check points, tumor suppressors and DNA 
repair. To promote cell proliferation, Tax can stimulate the expression of cellular proteins controlling 
proliferation and survival [21–23]. Beyond that, Tax induces cellular genes which may contribute to 
HTLV-1-mediated pathogenesis such as the tumor marker and actin-bundling protein Fascin [24]. Tax 
is capable of stimulating cellular transcription by interacting with various signaling pathways such as 
both the canonical and non-canonical nuclear factor kappa B (NF-κB) pathways [21,22,25,26], cAMP 
response element-binding protein (CREB) and serum response factor (SRF) pathways [14,27]. In the 
early phase of tumor progression in patients, Tax is required to initiate transformation. By contrast, 
Tax is no longer expressed in many ATLL-cells in late stages of tumor progression, while Tax-induced 
signaling pathways are still maintained [28]. 
3. Differentiation of Human T Lymphocytes and HTLV-1-Persistence 
The differentiation status of a T cell is important for its survival. CD4
+ T cells, the main targets of 
HTLV-1-infection, are roughly grouped into different subsets (Figure 1), depending on the expression 
of surface markers, intracellular proteins and secretion of cytokines. Briefly, T cells are derived from 
progenitor cells in the bone marrow and become committed to their lineage in the thymus where they 
undergo positive and negative selection. Antigen recognition initiates proliferation of naïve T cells and Viruses 2011, 3                         
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their  differentiation  to  activated  T  cells  leading  to  changes  of  the  phenotype.  The  expression  of 
activation  markers  like  CD69  or  CD25  is  induced.  Depending  on  the  nature  of  antigen  and  the 
inflammatory milieu, antigen-specific effector T cells are induced to differentiate into at least two 
functionally distinct populations of effector T cells, T helper type 1 and 2 (Th1/ Th2) cells [29,30]. 
After pathogen elimination, most effector cells die, but some survive to form long-lived memory T cell 
(T mem) clones, which can be discriminated by function and surface markers into central and effector 
T mem [31].  
Figure 1. Model of CD4
+ T cell differentiation and of the phenotype of T cell subsets. The 
expression of characteristic surface expression markers (except FOXP3) is exemplified. 
Proliferation rate and susceptibility to apoptosis of the different T cell subsets are indicated 
by the bars on the right. Ag indicates antigen; dark bars, high; and, bright bars, low.  
 
 
Naturally occurring CD4
+ regulatory T cells (T reg) develop either in the thymus, or they arise from 
mature T cells recruited to the regulatory population in the periphery [32]. They comprise less than 
10% of the CD4
+ T cell pool in human blood. Functionally, T reg actively suppress activation of the 
immune  system  and  prevent  pathological  self-reactivity,  i.e.,  autoimmune  disease  [33].  Natural 
CD4
+ T reg are mostly CD25 (IL2RA)
high, CD127 (IL7R)
low, and they express FOXP3 as well as other 
characteristic markers [34–36]. Different T cell subsets do not only differ in their proliferation rates, 
but also in their susceptibility to apoptosis. T mem clones, for example, are fast-proliferating compared 
to naïve T cell clones [37]. Moreover, persisting T mem clones exhibit a low susceptibility to apoptosis 
after clearance of antigen as the survival protein BCL-2 (B-cell lymphoma 2) is upregulated [38].  Viruses 2011, 3                         
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The persistence of HTLV-1 in T cell clones, which are detectable over many years, suggests that 
proteins mediating survival and proliferation of long-lived T cell clones could be crucial for HTLV-1 
persistence  and,  thus,  be  potential  targets  of  its  oncoprotein  Tax.  Comparison  of  gene  expression 
profiles of HTLV-1-infected/transformed cells with those of uninfected cells revealed differences in 
the expression pattern [39–41] including Tax-dependent changes [42,43] and genes encoding surface 
proteins [44]. This review aims to depict various differentially expressed surface markers of HTLV-1-
transformed  cells,  which  may  be  important  for  communication  of  the  infected  cells  with  their 
environment, thereby contributing to viral persistence, survival and longevity of HTLV-1-transformed 
T cell clones. 
4. Lineage and Activation Markers of HTLV-1-Infected Cells 
HTLV-1-infected  cells  express  several  lineage  markers  on  their  surface.  For  ATLL  cells,  an 
international consensus meeting provided phenotypic properties of ATLL cells. Typical ATLL cells 
are characterized by integration of the HTLV-1 provirus, their nuclei are lobulated (flower cells), and 
phenotypically, they resemble mature CD4
+ T cells. ATLL cells express CD2, CD5, CD25 (IL2-RA), 
CD45R0,  CD29  (integrin  β  1),  T  cell  receptor  αβ,  and  HLA-DR  [45].  Lack  of  CD7  and  CD26 
(dipeptidyl peptidase 4) as well as diminished expression of CD3 are further characteristics [45,46]. 
Most ATLL cells are positive for CD52, although some patients lack this surface marker. Both CD52 
and  the  transferrin  receptor  (TFRC;  CD71)  are  also  overexpressed  on  HTLV-1-transformed  cells 
[45,47]. The immunophenotype of several HAM/TSP patients compared to uninfected controls has 
been shown before [48].  
In  HTLV-1-infected  cells,  several  immunoreceptors  and  activation  markers  are  deregulated. 
CD45R,  also  known  as  leukocyte  common  antigen  (LCA),  is  a  receptor-like  protein  tyrosine 
phosphatase (protein-tyrosine phosphatase receptor type c (PTPRC)), which regulates, amongst others, 
src family kinases. CD45R is expressed on all nucleated cells of the hematopoietic system and plays a 
critical role in antigen-stimulated proliferation of T lymphocytes. CD45R0, a light molecular weight 
isoform of CD45R, is expressed on activated T cells and memory T cells, while CD45RA, a high 
molecular weight isoform, is expressed on naïve T cells [49–51]. In vivo, CD4
+CD45R0
+ T cells are 
the main cell type infected with HTLV-1 [52]. In ATLL, the number of naïve T cells is reduced, while 
the number of memory T cells is increased and correlates with HTLV-1 provirus load [53]. Moreover, 
the pattern of CD45R0 expression can correlate with the clinical outcome of infection as acute-type 
ATLL patients with CD45R0
+ lymphocytes with intermediate expression show a better prognosis than 
those who lack CD45R0
+ cells with intermediate expression [54]. In HTLV-1-transformed cell lines, 
the  expression  pattern  of  CD45R0  is  divergent.  While  CD45R0  is  expressed  on  interleukin 
2(IL2)-dependent growing, Tax-low cells, it is absent on most IL2-independent growing, Tax-high cell 
lines [55]. To comprehensively analyze surface marker expression, we performed surface staining of 
several  differentiation  markers  including  CD45R0  which  are  typical  for  long-lived  T  cell  
populations and examined their expression by flow cytometry (Table 1). Our analysis included four  
types  of  HTLV-1-transformed  cell  lines  [41,43,56–58],  namely  (1)  HTLV-1  in  vitro-transformed, 
(2) ATLL-derived,  (3)  HAM/TSP-derived,  and  (4)  Tax-transformed  cell  lines.  With  regard  to 
CD45R0, we made comparable observations in similar cell types as CD45R0 was present in all cell 
lines except IL2-independent cell lines (C91-PL, MT-2, HuT-102). Viruses 2011, 3                         
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Table 1. Expression of differentiation markers on HTLV-1-transformed cells detected by flow cytometry. 
% Expression
a 
Origin  Name  IL2
b 
PTPRC 
CD45R0 
CD69 
CD80 
B7-1 
TNFRSF18 
GITR 
TNFRSF7 
CD27 
TNFRSF 
4-1BB 
TNFSF9 
4-1BBL 
CCR7 
EBI1 
IL2RA
c 
CD25 
IL7R 
CD127 
in vitro 
transformed 
C91-PL  no  0 +/− 0  0 +/− 0  82 +/− 17  41 +/− 3  0 +/−0  38 +/− 11  68 +/− 9  73 +/− 42  99 +/− 1  3 +/− 1 
MT-2  no  1 +/− 0  1 +/− 1  84 +/− 15  76 +/− 7  0 +/− 0  39 +/− 9  74 +/− 6  79 +/− 46  99 +/− 0  2 +/− 1 
ATLL-
derived 
HuT-102  no  5 +/− 2  0 +/− 0  88 +/− 11  99 +/− 0  0 +/− 0  65 +/− 5  70 +/− 9  63 +/− 36  100 +/− 0  1 +/− 1 
ATL-3  40  96 +/− 1  ND
d  74 +/− 8
c  72 +/− 9  0 +/− 0  21 +/− 5  19 +/− 6  21 +/− 12  99 +/− 0  2 +/− 2 
Champ  20  88 +/− 5
c  37 +/− 16  75 +/− 8
c  83 +/− 8  1 +/− 1  43 +/− 4  31 +/− 5  31 +/− 18  99 +/− 1  3 +/− 1 
JuanaW  20  89 +/− 5  45 +/− 13  60 +/− 1
c  92 +/− 3  0 +/− 0  18 +/− 6  24 +/− 8  55 +/− 32  98 +/− 0  2 +/− 2 
PaBe  20  96 +/− 3  5 +/− 1  66 +/− 13  39 +/− 0  0 +/− 0  7 +/− 3  21 +/− 3  19 +/− 11  100 +/− 1  3 +/− 2 
StEd  40  70 +/− 5  13 +/− 4  88 +/− 10  79 +/− 1  1 +/− 0  9 +/− 4  16 +/− 1  23 +/− 15  95 +/− 4  2 +/− 2 
HAM/TSP-
derived 
Abgho  40  95 +/− 1  31 +/− 15  67 +/− 10
c  71 +/− 10  1 +/− 0  26 +/− 8  18 +/− 4  27 +/− 2  95 +/− 1  4 +/− 2 
Eva  20  80 +/− 3  28 +/− 9
c  75 +/− 5
c  76 +/− 6  1 +/− 0  39 +/− 4  24 +/− 3  38 +/− 2  96 +/− 2  7 +/− 2 
Nilu  20  72 +/− 3  9 +/− 2
c  45 +/− 8
c  41 +/− 4  0 +/− 0  6 +/− 1  12 +/− 3  18 +/− 5  92 +/− 0  1 +/− 0 
Xpos  20  62 +/− 14  38 +/− 26
c  60 +/− 5  91 +/− 3  1 +/− 1  31 +/− 3  16 +/− 2  60 +/− 12  99 +/− 1  5 +/− 0 
Tax-
transformed 
Tesi  40  57 +/− 4
c  1 +/− 1
c  ND  93 +/− 2
c  0 +/−0
c  13 +/− 7
c  15 +/− 1  9 +/− 1
c  96 +/− 1  2 +/− 1
c 
a Values represent the mean of percent surface expression +/− SE (rounded values) as detected by flow cytometry of HTLV-1-transformed cell lines  
(n ≥ 3). Antibodies and protocol are given in the Appendix (Table 2); 
b Cell lines were grown without interleukin 2 (no IL2) or in the presence of either 20 
or 40 U/mL IL2; 
c Two experiments were performed; 
d ND, not done. 
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Among activation markers, CD80 (B7-1) and CD86 (B7-2) are upregulated on HTLV-1-infected 
cells [59,60]. Both are structurally similar members of the immunoglobulin superfamily expressed on a 
variety of hematopoietic cell types. CD80 and C86 interact with CD28 costimulatory and CTLA4 
inhibitory  receptors  on  T  cells  [61].  Following  infection  with  HTLV-1,  CD80  and  CD86  are 
constitutively  expressed  suggesting  that  HTLV-1-infected  CD80
+/CD86
+  T  cells  serve  as  antigen 
presenting cells, leading to a sustained proliferation of T cells [62]. In freshly-isolated PBMC from 
ATLL patients, both CD80 and C86 were upregulated after short-term culture and spontaneous Tax 
expression [63]. We confirmed consistent overexpression of CD80 on all types of HTLV-1-transformed 
cell lines including the Tax-transformed cell line Tesi, whereas the expression profile of the early T 
cell activation marker CD69 was divergent (Table 1). In ATLL patient cells, however, CD69 was not 
expressed, but could be induced following mitogenic stimulation [64]. 
5. Costimulatory Receptors of the Tumor Necrosis Factor Receptor (TNFR) Superfamily  
Activation of T cells requires two different signals including (1) a signal provided by the T cell 
receptor complex after recognition of peptides presented by MHC II molecules on antigen-presenting 
cells,  and  (2),  a  second,  costimulatory  signal  which  is  provided  by  CD28,  a  member  of  the 
immunoglobulin  superfamily,  upon  ligation  with  CD80  or  CD86.  Generally,  costimulatory  signals 
provided by CD28 are necessary to initiate T cell activation. The same holds true for costimulatory 
receptors of the tumor necrosis factor (TNF) receptor superfamily, although most of them deliver their 
signals after CD28 [65].  
The TNF receptor (TNFR) superfamily comprises three groups: (1) death domain (DD)-containing 
receptors,  (2)  decoy  receptors,  and  (3)  TNF  receptor  associated  factor  (TRAF)  binding  receptors 
including costimulatory receptors [65]. Although HTLV-1-transformed cells express receptors of all 
three  subtypes  [66–69],  costimulatory  TRAF  binding  TNFR  will  be  focused  on  here  due  to  their 
importance for proliferation.  
TRAF  binding  receptors  are  type  I  transmembrane  proteins  that  contain  intracellular  motifs  
of 4-6 amino acids which function to recruit TRAF proteins. In general, these receptors are associated 
with cellular activation, differentiation, and survival signaling. Upon binding of ligands, which are 
type  II  cell  surface  glycoproteins,  signaling  pathways  are  induced  and  determined  by  intracellular 
TRAFs  [65,70].  Activation  of  the  costimulatory  TNF  receptors  OX40  (TNFRSF4)  and  4-1BB 
(TNFRSF9), e.g., leads to activation of the NF-κB and the phosphoinositide-3-kinase (PI3K)/AKT 
pathways,  and  to  increased  expression  of  anti-apoptotic  molecules  including  BCL-2,  BCL-XL 
(BCL2L1) and BFL1 (BCL2A1) [70]. As a consequence, 4-1BB (TNFRS9) and OX40 (TNFRSF4) 
mediate  survival  and  proliferation  of  long-lived  T  cell  clones  and  could  therefore  be  crucial  for 
HTLV-1 persistence and, thus, be potential targets of its oncoprotein Tax. While being mostly absent 
from naïve T cells, they are present on long-lived T lymphocyte clones like T reg and T mem [35,70]. 
In the latter, they can augment proliferation and survival by providing anti-apoptotic signals several 
days  after  a  naïve  T  cell  encounters  antigen.  These  signals  allow  continued  turnover  of  cells  and 
provide survival signals to prevent excessive T cell death. Consequently, the number of effector cells 
entering the memory pool is increased [38,70,71].  
Several  costimulatory  receptors  and  ligands  of  the  TNF  family  are  deregulated  in 
HTLV-1-transformed cells. gp34 was first identified in cells expressing HTLV-1 [72]. Its expression is Viruses 2011, 3                         
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inducible by Tax via NF-κB responsive elements in the promoter [73]. Later, gp34 was described as a 
type II transmembrane protein belonging to the TNF family, TNFSF4, and found to be the ligand for 
OX40 (OX40L) [74,75]. OX40L is expressed on normal T and B cells upon antigen stimulation while 
mitogens, phorbol ester, ionophores and IL-2 fail to induce OX40L in human T cells. In addition to 
OX40L,  the  receptor  OX40  (TNFRSF4)  is  specifically  upregulated  in  HTLV-1-infeceted  cells  by 
Tax-mediated promoter upregulation [76], suggesting an autocrine loop. In contrast to OX40L, OX40 
was also present on freshly isolated ATLL cells and found on infiltrating cells of skin biopsies of 
ATLL patients [63,77]. Moreover, expression of OX40 increased significantly after cultured ATLL 
cells expressed high amounts of Tax spontaneously [63]. 
The  costimulatory  TNFR  GITR  (glucocorticoid-induced  tumor  necrosis  factor  receptor 
family-related  gene;  TNFRSF18;  AITR)  is  expressed  at  low  levels  on  resting  T  cells,  but  it  is 
upregulated upon activation or antigen-stimulation of CD4
+ and CD8
+ T cells. On naturally occurring 
T reg, GITR is constitutively expressed and important for maintenance of T reg in the periphery, while 
it is not essential for their development [78]. Overexpression of GITR was identified in the presence of  
HTLV-1 using massively parallel signature sequencing [79]. In addition, a high frequency of GITR 
surface  expression  was  a  unique  feature  of  all  different  types  of  HTLV-1-transformed  cell  lines 
(Table 1) and extends earlier observations of protein expression in in vitro-transformed cell lines [79] 
and of transcript expression in primary ATLL cells [80].  
Although  both  CD40  (TNFRSF5)  and  its  ligand  CD40L  can  be  upregulated  by  Tax,  CD40L 
expression  is  absent  in  HTLV-1-transformed  cell  lines  due  to  epigenetic  mechanisms,  but  can  be 
restored  in  cells  from  ATLL  patients.  This  indicates,  that  CD40L  is  downregulated  by  distinct 
mechanisms in HTLV-I transformed cell lines and ATLL patients [64,81]. Upregulation of the ligand 
CD70 (TNFSF7, CD27L) was identified in freshly HTLV-1-in vitro immortalized peripheral blood 
mononuclear  cells  (PBMC)  compared  to  proliferating  T  cells  using  gene  expression  arrays  and 
Northern blot analysis [39]. Expression of CD70 protein could also be detected on HTLV-1-transformed 
cell lines and on fresh PBMCs from ATLL patients [44]. Thus far, CD70 expression could not be 
associated  with  survival  advantages  of  HTLV-1-transformed  cells  [44].  Interestingly,  the  natural 
receptor of CD70, CD27 (TNFRSF7), is not expressed on HTLV-1-transformed cells (Table 1) ruling 
out a possible autostimulatory mechanism of the CD27/CD70 receptor-ligand pair. 
To identify additional costimulatory receptors, which are Tax-dependently expressed, our group 
screened mRNA from T cells with repressible Tax expression and found that among all costimulatory 
receptors, transcripts of 4-1BB (TNFRSF9) were increased most strongly [43]. Upregulation of 4-1BB 
was  a  consistent  feature  of  HTLV-1-transformed  cell  lines  (Table  1)  and  was  caused  by  efficient 
transactivation of the 4-1BB promoter by Tax via the NF-κB pathway. Additionally, the ligand of 
4-1BB,  4-1BBL  (TNFSF9)  was  expressed  on  HTLV-1-transformed  cells  (Table  1)  suggesting 
auto-stimulation. In the presence of Tax, 4-1BB expression was strongly stimulated on the surface of 
CD4
+ T cells isolated from HTLV-1-infected patients. [43]. Thus, the costimulatory receptor 4-1BB is 
a target of Tax stimulation in cultured cells and in patients, and is likely to support the survival of 
HTLV-1-infected T-cell clones. Taken together, the presence of several costimulatory receptors and 
their ligands on HTLV-1-transformed cells suggests that costimulatory signals contribute to growth 
and survival of the infected cell, and therefore favor a transformed phenotype. Viruses 2011, 3                         
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6. Chemokine Receptors 
Chemokine receptors belong to the family of G protein-coupled receptors (GPCRs), which contain 
seven transmembrane domains. Upon binding of the respective ligand, they mediate transduction of 
signals via intracellularly located heterotrimeric G-proteins. Several chemokines and their receptors 
are involved in migration of lymphocytes [82]. As ATLL is frequently accompanied by infiltrations of 
leukemic cells into various organs like lymph nodes or skin [83], an altered expression pattern of 
chemokine receptors and their ligands may be expected. 
Over-expression  of  the  secreted,  anti-apoptotic  chemokine  I-309,  as  well  as  expression  of  its 
cognate receptor CCR8 on ATLL-derived cells, were suggested to generate an anti-apoptotic autocrine 
loop which could contribute to the growth of ATLL-cells [41]. CCR9, which is involved in T-cell 
homing to the gastrointestinal tract, was found in ATLL cells infiltrating the gastrointestinal tract and 
expressed on cell lines carrying HTLV-1 [84]. Chemokine receptor 7 (CCR7/ EBI1/ CMKBR7) is 
naturally expressed on central T mem [37] and required for in vivo function of CD4
+CD25
+ T reg [85]. 
Enhanced expression of CCR7 in ATLL patients correlated with lymphoid organ involvement [83]. 
Additionally, CCR7 expression was also a consistent feature of all HTLV-1-transformed cell lines 
(Table 1), although the expression levels exhibited a broader variation and lacked continuity, which 
may be due to receptor internalization, a characteristic of chemokine receptors. CCR7 overexpression 
could be an important mechanism for the establishment of a persistent viral infection of lymphoid cells 
which is not limited to HTLV-1 infection. Other persisting viruses such as the B-lymphotropic EBV 
are  known  to  transactivate  CCR7  expression  via  the  EBV  nuclear  antigen  2  (EBNA2)  [86]. 
Interestingly,  besides  CCR7,  additional  chemokine  receptors  including  the  skin  homing  receptors 
CCR4 and CCR10 are also expressed on ATLL cells from patients [87]. Among these receptors, CCR4 
has been studied most intensively because of the association between predominant CCR4 expression  
on  ATLL  cells  with  skin  involvement  and  unfavorable  outcome  [88,89],  CCR4  has  been  
successfully tested as a target for immunotherapy in ATLL in a phase I study [90,91]. Interestingly, 
HTLV-1-infected T cells Tax-dependently produce CCL22, the ligand of CCR4, too. Thereby, they 
can selectively interact with CCR4
+CD4
+ T cells, resulting in preferential transmission of HTLV-1 to 
CCR4
+CD4
+ T cells [92]. In conditionally Tax-expressing lymphocytes, activation of SDF-1/CXCR4 
signaling  correlated  with  Tax  expression  [93].  This  pathway  was  shown  to  be  important  in  other 
systems, too, as the use of a CXCR4 antagonist suppressed migration of cultured cells from ATLL 
patients and of murine lymphoblastoid cells from HTLV-I Tax transgenic mice [94]. Taken together, 
chemokines and their receptors are massively exploited during HTLV-1-mediated pathogenesis.  
7. Interleukin Receptors 
Tax stimulates expression of cellular interleukins and their receptors including interleukin 2 (IL2) 
and the alpha subunit of the IL2 receptor (IL2RA, CD25), IL13 and the receptor chains IL4RA and 
IL13RA, IL15 and its receptor IL15 (reviewed by [22]), as well as IL21 and the IL21 receptor (IL21R) 
[95].  By  contrast,  low  IL7R  (CD127)  expression  is,  apart  from  ATLL-derived  cell  lines  [96],  a 
common feature of all types of HTLV-1-transformed cells (Table 1).  
Among the interleukin receptors, IL2RA was the first cellular gene reported to be upregulated by 
Tax [97,98]. High expression of IL2RA is also a consistent feature of HTLV-1-transformed cell lines Viruses 2011, 3                         
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(Table 1). Together with the subunits IL2RB (CD122) and the common γ chain, IL2RG (CD132), 
IL2RA forms a functional IL2 receptor (IL2R). In addition to IL2RA, Tax stimulates the IL2 promoter 
[99–101] which led to the hypothesis of T cell proliferation through an autocrine IL2/IL2R loop in 
HTLV-1-transformed  cells [22]. However, most HTLV-1/Tax-immortalized cells or ATLL-patient-
derived cells in culture do not express high levels of IL2 [102] and even require exogenous IL2 for 
their growth [19,56,103]. Therefore, the role of an IL2/IL2R autocrine loop in leukemogenesis and 
transformed growth in culture remains to be determined. 
Additionally, Tax also induces expression of IL15 [104], which signals through a functional IL15 
receptor composed of the Tax-inducible IL15RA chain [105] and two components of the IL2 receptor, 
IL2RB and the common γ chain IL2RG. The existence of an IL15 autocrine loop was suggested in 
PBMC from HAM/TSP patients [106]. IL9, which unlike its IL9RA chain is also activated by Tax, 
shares the common γ chain with IL2 and IL15 receptors and functions by a paracrine mechanism in 
ATLL [107]. A recent study emphasized the relevance of IL2-, IL9-, and IL15-mediated signaling for 
HTLV-1-associated  pathogenesis.  Ex  vivo  spontaneous  proliferation  of  PBMCs  from  ATLL  and 
HAM/TSP was inhibited using a selective inhibitor of Jak3, which blocks signaling mediated by IL2, 
IL9 and IL15 [108]. 
The IL4/IL13 receptor complex provides stimulatory signals via the IL4RA chain. In contrast to IL4, 
IL13  is  upregulated  and  secreted  in  HTLV-transformed  cells  and  in  cultured  ATLL-cells  derived  
from  patients  [109,110].  In  HTLV-cells,  IL13  expression  is  upregulated  by  Tax  dependent  on  a 
NF-κB-responsive element in the promoter [111]. IL13 is linked to leukemogenesis, since in both 
Hodgkin's  lymphoma  cells  and  HTLV-1-transformed  cells,  it  seems  to  act  through  an  autocrine 
mechanism [22]. 
8. Adhesion Molecules on HTLV-1-Infected Cells 
The Tax protein also affects T cell interactions as it stimulates the expression of adhesion molecules 
like the CD2 receptor CD58 (LFA-3), intercellular adhesion molecule-1 (ICAM-1, CD54) [112,113], 
and vascular cell adhesion molecule 1 (VCAM-1) [114]. While VCAM-1 could be detected on freshly 
isolated T cells from HAM/TSP patients [115], ICAM-1 and LFA-1 were downregulated on ATLL cell 
lines [116]. By contrast, another study showed consistent and high expression of  ICAM-1 and an 
active  form  of  LFA-1,  which  is  a  counter-receptor  for  ICAM-1,  on  fresh  PBMC  from  ATLL 
patients. It was proposed that the proliferation of ATLL cells occurs in sequential events, including 
(1) homotypic  and  calcium-dependent  adhesion  through  LFA-1/ICAM-1,  (2)  signal  transduction 
through these adhesion molecules, (3) production of cytokines, and (4) proliferation [117]. Not only 
proliferation of the infected cell population, but also of uninfected cells may be regulated by adhesion 
molecules.  In  coculture  experiments,  irradiated  or  fixed  HTLV-1-infected  clones  from  HAM/TSP 
patients  induced  the  proliferation  of  autologous,  uninfected  T  cells  dependent  on  CD2/LFA-3, 
LFA-1/ICAM1, and CD25 [118]. This hints at bystander effects of adhesion molecules on uninfected 
cells. In HTLV-1-infected T cells, stimulation of ICAM-1 on the cell surface in combination with 
intracellular Tax protein expression is sufficient to trigger polarization of the microtubule-organizing 
center (MTOC) at the virological synapse [119,120].  
Interestingly, the HTLV-1 accessory protein p12 downregulates ICAM-1, ICAM-2 and MHC class 
I molecules, thereby avoiding immune recognition [121]. Additionally, the initially described capacity Viruses 2011, 3                         
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of p12 to increase T cell contact by clustering of lymphocyte function-associated antigen-1 (LFA-1) 
[122],  was  mapped  to  the  viral  p8  protein,  which  is  generated  from  p12  by  removal  of  an 
endoplasmatic reticulum retention signal. p8 also increases inter-cellular conduits thereby enhancing 
cellular communication and virus transmission [123,124].  
Recently, the cell adhesion molecule tumor suppressor in lung cancer (TSLC1; IGSF4), a member 
of the immunoglobulin superfamily, was found to be overexpressed in acute-type ATLL cells [125]. 
Due to the ability of TSLC1 to enhance self-aggregation of ATLL cells and their adhesion to vascular 
endothelial  cells,  the  authors  speculated  that  TSLC1  may  participate  in  tissue  invasion,  which  is 
frequently  found  in  ATLL.  Function  and  properties  of  surface  molecules  important  for  adhesion, 
binding and entry of HTLV-1 including glucose transporter 1 (GLUT1), neuropilin 1 (NRP1) and 
heparan sulfate proteoglycans have recently been reviewed by Ghez et al. [126].  
9. Contribution of Cell Surface Markers to Longevity and Pathogenesis  
The  data  summarized  in  this  review  provide  evidence  that  HTLV-1-transformed  cells  assume 
biological features of long-lived T cell clones as they express characteristic expression markers like 
CD4
+CD25
+CD45R0
+CD127
low4-1BB
+GITR
+CCR7
+ on their surface. These differentiation markers 
include, amongst others, characteristic lineage markers, costimulatory receptors, chemokine receptors, 
interleukin  receptors  and  adhesion  molecules.  Signals  provided  by  the  receptors  and  their  ligands 
might contribute to survival and growth of the HTLV-1-infected cell, and thus, contribute to longevity 
of  infected  T  cell  clones.  Moreover,  the  infiltrations  observed  in  ATLL  could  be  supported  by 
expression of several chemokine receptors and adhesion molecules.  
Expression of many of these surface markers could be attributed to expression of the viral Tax 
oncoprotein. However, there are differences in viral gene expression between cell lines and freshly 
isolated PBMC from ATLL patients. While Tax is uniformly expressed in cell lines with varying 
amounts [58], most freshly isolated ATLL patient cells do not express Tax spontaneously [68,127]. 
This can be explained by genetic modifications of Tax, DNA methylation or deletions in the 5’ LTR of 
the  provirus  resulting  in  silencing  of  viral  gene  expression  (reviewed  in  [127]).  Paradoxically,  a 
persistently activated cytotoxic T lymphocyte (CTL) response to Tax, the immunodominant target that 
is  recognized  by  CTL,  is  found  in  most  infected  patients  [68,128,129]  and  thought  to  regulate 
viral gene expression. Removal of CD8
+ T cells from patient samples ex vivo leads to spontaneous 
expression  of  Tax  after  short-term  culture  [68].  Concomitant  with  the  loss  of  Tax  expression  in 
ATLL-patients, several of the markers, like 4-1BB, are, as indicated before, induced after spontaneous 
expression of Tax in CD4
+ T cells of ATLL patients. Other markers, like CCR4, are expressed in 
ATLL patient samples independent of Tax expression [130]. It is unlikely that all markers regulated by 
Tax and/or involved in immune-signaling are expressed at once and at high levels in PBMC in ATLL 
cells as this would require permanent Tax expression in several cases and induce immune response. 
The individual role of each marker, its temporal regulation and fine-tuning of its expression during 
HTLV-1-persistence  and  development  of  pathogenesis  remains  to  be  analyzed  in  more  detail  in 
infected ATLL patients.  
Despite several therapeutic approaches, ATLL still has a very poor prognosis due to resistance to 
chemotherapy.  Interestingly,  targeting  of  several  of  the  described  cellular  surface  proteins  on 
malignant cells has already been used as an alternative therapeutic approach [131,132]. Monoclonal Viruses 2011, 3                         
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antibodies targeting IL2RA (CD25), CD2, CD52, and CCR4 were already tested in clinical trials [45]. 
Therefore, further investigation of the surface phenotype may elucidate novel targets for therapy of 
HTLV-1-associated disease. 
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Appendix 
Table 2. Monoclonal antibodies and isotype controls used in flow cytometry. 
Antigen  Conjugate  Isotype  Clone  Origin  Company 
CCR7  FITC  IgG2a  150503  mouse 
R&D systems, Wiesbaden, 
Germany 
CD25 (IL2RA)  PE  IgG1  M-A251  mouse  BD, San Jose, CA, USA 
CD27 (TNFRSF7)  FITC  IgG1  O323  mouse 
NatuTec, Frankfurt/M., 
Germany 
CD45RO (PTPRC)  FITC  IgG2a  UCHL1  mouse  NatuTec 
CD69  PE  IgG1  L78  mouse  BD 
CD80  FITC  IgG1  MEM-233  mouse 
EuroBioSciences, 
Friesoythe, Germany 
CD127 (IL7R)  PE  IgG1  hIL-7R-M21  mouse  BD 
CD137 (TNFRSF9/ 4-1BB)  FITC  IgG1  4B4-1  mouse  AbD Serotec, Oxford, UK 
CD137L (TNFSF9/ 4-1BBL)  R-PE  IgG1  C65-485  mouse  BD 
GITR (TNFRSF 18)  FITC  IgG1  110416  mouse  R&D Systems 
IgG1 isotype control  R-PE  IgG1  MOPC-21  mouse  BD 
IgG1 isotype control  FITC  IgG1  MOPC-21  mouse  BD 
IgG2a isotype control  FITC  IgG2a    mouse  NatuTec 
IgG indicates immunoglobulin G; FITC, fluorescein isothiocyanate; PE, phycoerythrin. 
Analysis of Surface Expression by Flow Cytometry 
Expression of differentiation markers was analysed by flow cytometry. Briefly, 1 × 10
6 cells were 
washed in FACS-buffer (PBS without Ca
2+ and Mg
2+ containing 5% FCS and 0.01 % NaN3) and fixed 
in 2% paraformaldehyde in PBS. Thereafter, cells were stained with monoclonal antibodies (Table2) 
and the respective isotype control antibodies for 45 min on ice. After two wash steps in FACS-buffer, 
fluorescence was measured on a flow cytometer (FACS Calibur, BD, San Jose, CA, USA). Data were 
evaluated with FCS Express version 3 [133] and the mean of % positivity of surface expression +/− 
standard error (SE) of three independent experiments was calculated.  
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